keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine tumor metastasic treatment

keyword
https://www.readbyqxmd.com/read/29145267/osteoblastic-bone-metastases-from-neuroendocrine-tumor-net-of-unknown-origin-detected-by-18fluorocholine-pet-ct-and-its-comparison-with-68gallium-dotatoc-pet-ct-case-report-and-review-of-the-literature
#1
Alberto Bongiovanni, Federica Recine, Monica Celli, Giulia Marcantognini, Flavia Foca, Chiara Liverani, Valentina Fausti, Alessandro De Vita, Giacomo Miserocchi, Laura Mercatali, Dino Amadori, Toni Ibrahim
RATIONALE: Choline (CH) positron emission tomography (PET)/computed tomography (CT) with fluorine 18 (F) CH is increasingly used not only to evaluate patients with biochemically recurrent prostate cancer but also to assess metastatic lesions that are difficult or impossible to identify using more conventional modalities. Our experience with CH PET/CT has shown that it can also be used for many other malignancies. PRESENTING CONCERNS: A 71-year-old male with a neuroendocrine tumor (NET) of unknown origin showed osteoblastic bone metastases positive to F-CH PET...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29127554/is-there-any-role-for-minimally-invasive-surgery-in-net
#2
REVIEW
M Thomaschewski, H Neeff, T Keck, H P H Neumann, T Strate, E von Dobschuetz
Neuroendocrine tumors (NET) represent the variability of almost benign lesions either secreting hormones occurring as a single lesion up to malignant lesions with metastatic potential. Treatment of NET is usually performed by surgical resection. Due to the rarity of NET, surgical treatment is mainly based on the experience and recommendations of experts and less on the basis of prospective randomized studies. In addition, the development and establishment of new surgical procedures is made more difficult by their rarity...
November 11, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/29120653/-thyroid-carcinomas-the-present-view-on-diagnostics-and-therapy
#3
Petr Vlček, Dana Nováková, Rami Katra
Thyroid carcinoma (TC) represents 1-2 % of all human tumors, and is the seventh most common tumor. Women are in large majority among new patients. For women, this is the fifth most common tumor. In the Czech Republic, 1 143 new cases of TC were diagnosed in 2015. It is the tumor with the highest increase in incidence. Among newly diagnosed tumors, most of those are differentiated thyroid gland carcinomas (DTCs) originating from follicular thyroid cells. These tumors are follicular and papillary carcinomas and Hurthle carcinoma, accounting for 95 % of new cases...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29113001/the-impact-of-high-end-ultrasound-in-the-management-of-a-patient-with-neuroendocrine-tumor-of-the-ileum
#4
Tatjana Schmidt, Julia M Schwarz, Martina Steurer, Martin Goetz, Susann-Cathrin Olthof, Nisar P Malek, Bita Boozari
Diagnostic imaging of jejuno-ileal neuroendocrine tumors (NETs) has been described as challenging. Follow-up requires the detection of metastatic spread as well as screening for local recurrence. Multimodal imaging concepts must often be applied.We report the case of a 45-year-old man with a history of ileal NET. At 2 points in follow-up of our patient, information provided by high-end ultrasound changed prognosis and treatment considerably: when positron emission tomography/computed tomography newly detected suspected hepatic metastases, contrast-enhanced ultrasound correctly identified the lesions as intrahepatic vascular shunts...
November 7, 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29108359/surgical-resection-of-primary-tumor-improves-survival-of-pancreatic-neuroendocrine-tumor-with-liver-metastases
#5
Lianyuan Tao, Dianrong Xiu, Abuduhaibaier Sadula, Chen Ye, Qing Chen, Hanyan Wang, Zhipeng Zhang, Lingfu Zhang, Ming Tao, Chunhui Yuan
This study investigates survival of patients diagnosed with pancreatic neuroendocrine tumor with liver metastases based on local treatment on the primary tumor. Patients diagnosed with stage IV PNET between 2010 and 2014 were identified from the Surveillance Epidemiology and End Results database. Cancer-Specific Survival and Overall Survival were examined. A total of 191 patients with pancreatic neuroendocrine tumor with liver metastases were included in this analysis. There were 47 patients (24.6%) who received surgical resection and 144 (75...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29105026/metastatic-non-small-cell-lung-carcinoma-a-mimic-of-primary-breast-carcinoma-case-series-and-literature-review
#6
Rola H Ali, Catalin Taraboanta, Tareq Mohammad, Malcolm M Hayes, Diana N Ionescu
Metastatic tumors to the breast are rare but constitute a major diagnostic dilemma. Of these, non-mammary carcinomatous metastases to the breast are particularly challenging and, without a clinical history, may be extremely difficult to distinguish from primary breast carcinoma (PBC). We specifically studied metastatic tumors of pulmonary origin, as the lung is one of the major primary sites for carcinomatous metastasis to breast. Sixteen metastatic lung tumors to the breast were identified in our archives between 1996 and 2017 including 12 non-small cell lung carcinomas (NSCLC), one large-cell neuroendocrine, one atypical carcinoid, and two small-cell carcinomas...
November 5, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29102861/an-isolated-metachronous-metastasis-to-the-adrenal-gland-from-a-pancreatic-neuroendocrine-tumor-a-case-report
#7
Yasunaru Sakuma, Naohiro Sata, Kazuhiro Endo, Yoshikazu Yasuda, Shinichiro Yokota, Yoshinori Hosoya, Atsushi Shimizu, Hirofumi Fujii, Daisuke Matsubara, Noriyoshi Fukushima, Shoko Asakawa, Yuuki Kawarai Shimada, Chieko Kawarai Lefor, Alan Kawarai Lefor
INTRODUCTION: Pancreatic neuroendocrine tumors are rare. Treatment includes aggressive local management of the primary lesion and metastases, and systemic somatostatin. This is the first report of an isolated metachronous metastasis to the adrenal gland from a pancreatic neuroendocrine tumor that presented 90 months after the primary tumor. PRESENTATION OF CASE: The patient presented as a 53yo man with a left upper quadrant mass and synchronous metastases to the spleen and liver (pancreatic neuroendocrine tumor T4N0M1, Stage IV), which were resected (CD56-, synaptophysin+, chromogranin+, Ki-67<1%)...
October 19, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29099418/temozolomide-treatment-of-a-malignant-pheochromocytoma-and-an-unresectable-max-related-paraganglioma
#8
Alfonso M Ferrara, Giuseppe Lombardi, Ardi Pambuku, Domenico Meringolo, Roberta Bertorelle, Margherita Nardin, Francesca Schiavi, Maurizio Iacobone, Giuseppe Opocher, Vittorina Zagonel, Stefania Zovato
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors with a strong genetic background. The mainstay of treatment for PCC/PGLs is surgery. However, for unresectable lesions, no curative treatment is currently available. Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs. We report two cases of PCC/PGLs treated with TMZ. Case 1 is a 51-year-old man with local and distant recurrence (liver and bone metastases) of right adrenal PCC...
November 2, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29083468/pancreatic-neuroendocrine-tumors-state-of-the-art-diagnosis-and-management
#9
REVIEW
Aaron Lewis, Daneng Li, John Williams, Gagandeep Singh
The incidence of pancreatic neuroendocrine tumors (PNETs) has significantly increased in recent years, although this may reflect better detection and improved diagnosis, in addition to a true increase in incidence. The majority of PNETs are nonfunctional; up to half of nonmetastatic PNETs will present incidentally, and 85% will develop metastases over their lifetime. Treatment of PNETs is largely dictated by their heterogeneous nature and usually indolent behavior. Surgery is a mainstay of treatment, both in early PNETs and in metastatic disease...
October 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29081018/treatment-for-malignant-pheochromocytomas-and-paragangliomas-5%C3%A2-years-of-progress
#10
REVIEW
Paola Jimenez, Claudio Tatsui, Aaron Jessop, Sonali Thosani, Camilo Jimenez
PURPOSE OF REVIEW: The purpose of this manuscript is to review the progress in the field of therapeutics for malignant pheochromocytomas and sympathetic paraganglioma (MPPG) over the past 5 years. RECENT FINDINGS: The manuscript will describe the clinical predictors of survivorship and their influence on the first TNM staging classification for pheochromocytomas and sympathetic paragangliomas, the treatment of hormonal complications, and the rationale that supports the resection of the primary tumor and metastases in patients with otherwise incurable disease...
October 28, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/29061283/liver-resection-for-metastases-not-of-colorectal-neuroendocrine-sarcomatous-or-ovarian-ncnso-origin-a-multicentric-study
#11
Ismail Labgaa, Ksenija Slankamenac, Erik Schadde, Ghalib Jibara, Kutaiba Alshebeeb, Gilles Mentha, Pierre-Alain Clavien, Myron Schwartz
BACKGROUND: Liver resection is a well-established treatment for colorectal, neuroendocrine and sarcomatous metastases but remains ill-defined for metastases from other primary sites. This study aimed to analyze the outcomes of hepatic resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin and to identify predictors of outcome. METHODS: Retrospective analysis of patients undergoing resection for NCNSO metastases in three western centers...
October 7, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/29061059/bone-metastases-in-neuroendocrine-tumors
#12
R Zamborsky, A Svec, M Kokavec, S Galbavy
Neuroendocrine tumors arise from various cells that form a part of the endocrine system and account for a small number of cases encountered by oncologists in clinical practice. The clinical incidence of these tumors used to be low, and newer imaging modalities have now begun to be used for detecting bone metastases at an earlier stage. Bone metastases arising from neuroendocrine tumors are a well-recognized complication. Their presence carries along a poor prognosis. Clinical symptoms are similar to those encountered in other forms of cancer that are complicated by bone metastasis...
2017: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29049611/association-of-a-prophylactic-surgical-approach-to-stage-iv-small-intestinal-neuroendocrine-tumors-with-survival
#13
Kosmas Daskalakis, Andreas Karakatsanis, Ola Hessman, Heather C Stuart, Staffan Welin, Eva Tiensuu Janson, Kjell Öberg, Per Hellman, Olov Norlén, Peter Stålberg
Importance: Primary tumor resection and mesenteric lymph node dissection in asymptomatic patients with stage IV small intestinal neuroendocrine tumors (SI-NETs) are controversial. Objective: To determine the association of locoregional surgery (LRS) performed at diagnosis with outcomes in patients with asymptomatic SI-NETs and distant metastases. Design, Setting, and Participants: This cohort study included asymptomatic patients with stage IV SI-NETs diagnosed from January 1, 1985, through December 31, 2015, and identified using the prospective database of SI-NETs from Uppsala University Hospital, Uppsala, Sweden...
October 19, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29018912/a-nationwide-population-based-study-on-the-survival-of-patients-with-pancreatic-neuroendocrine-tumors-in-the-netherlands
#14
C G Genc, H J Klümpen, M G H van Oijen, C H J van Eijck, E J M Nieveen van Dijkum
BACKGROUND: Large population-based studies give insight into the prognosis and treatment outcomes of patients with pancreatic neuroendocrine tumors (pNETs). Therefore, we provide an overview of the treatment and related survival of pNET in the Netherlands. METHODS: Patients diagnosed with pNET between 2008 and 2013 from the Netherlands Cancer Registry were included. Patient, tumors and treatment characteristics were reported. Survival analyses with log-rank testing were performed to compare survival...
October 10, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28975561/liver-transarterial-embolizations-in-metastatic-neuroendocrine-tumors
#15
REVIEW
Louis de Mestier, Magaly Zappa, Olivia Hentic, Valérie Vilgrain, Philippe Ruszniewski
The management of patients with well-differentiated neuroendocrine tumors (NET) and non-resectable liver metastases is challenging. Liver-directed transarterial embolization (TAE), transarterial chemo-embolization (TACE) and selective internal radiation therapy (SIRT) have a place of choice among other treatment modalities. However, their utilization relies on a low level of proof, due to the lack of prospective data, the absence of comparative studies and considerable heterogeneity between local practices...
October 3, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28927133/benefit-of-rebiopsy-for-deciding-treatment-strategy-in-rectal-cancer-a-case-report
#16
Kenta Kawasaki, Yasuo Hamamoto, Takeshi Suzuki, Kenro Hirata, Yasutaka Sukawa, Akiyoshi Kasuga, Yuichiro Hayashi, Hiromasa Takaishi, Kaori Kameyama, Takanori Kanai
Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28920501/kidney-dosimetry-during-177-lu-dotatate-therapy-in-patients-with-neuroendocrine-tumors-aspects-on-calculation-and-tolerance
#17
Mattias Sandström, Ulrike Garske-Román, Silvia Johansson, Dan Granberg, Anders Sundin, Nanette Freedman
BACKGROUND: Fractionated therapy with (177)Lu-DOTATATE has been reported to be an effective treatment for patients with metastasized neuroendocrine tumors. To optimize the treatment, absorbed doses to risk organs are calculated for the individual patient. For each organ, absorbed dose due to activity in the organ itself (self-dose) and that originating from other organs (cross-dose) are calculated from serial measurements to obtain the activity distribution following treatment. The main aim of the present work were to calculate the cross-dose contribution to the total absorbed kidney dose...
September 18, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28888827/tumor-dose-response-in-yttrium-90-resin-microsphere-embolization-for-neuroendocrine-liver-metastases-a-tumor-specific-analysis-with-dose-estimation-using-spect-ct
#18
Orapin Chansanti, Younes Jahangiri, Yusuke Matsui, Akira Adachi, Yindee Geeratikun, John A Kaufman, Kenneth J Kolbeck, Jeffrey S Stevens, Khashayar Farsad
PURPOSE: To evaluate dose-response relationship in yttrium-90 ((90)Y) resin microsphere radioembolization for neuroendocrine tumor (NET) liver metastases using a tumor-specific dose estimation based on technetium-99m-labeled macroaggregated albumin ((99m)Tc MAA) single photon emission computed tomography (SPECT)-CT. MATERIALS AND METHODS: Fifty-five tumors (mean size 3.9 cm) in 15 patients (10 women; mean age 57 y) were evaluated. Tumor-specific absorbed dose was estimated using a partition model...
November 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28868202/a-thoracic-vertebral-localization-of-a-metastasized-cutaneous-merkel-cell-carcinoma-case-report-and-review-of-literature
#19
Rosario Maugeri, Antonella Giugno, Roberto G Giammalva, Carlo Gulì, Luigi Basile, Francesca Graziano, Domenico G Iacopino
BACKGROUND: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin tumor, which may be related to sun exposure. It can metastasize to lungs, liver and bone, leading to severe morbidity and mortality. Vertebral metastases from MCC are rare. The authors report the tenth case in the literature, a 59-year-old patient with MCC, which was primarily localized in the scalp, and later provoked distant metastasis to the thoracic spinal column. CASE DESCRIPTION: A 59-year-old woman was admitted at our Unit of Neurosurgery with a 4-month history of progressive and severe dorsal back pain, without neurological signs...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/28855982/peritoneal-metastases-of-rare-carcinomas-treated-with-cytoreductive-surgery-and-hipec-a-single-center-case-series
#20
Andreas Brandl, Christina Barbara Zielinski, Wieland Raue, Johann Pratschke, Beate Rau
INTRODUCTION: In selected cases, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for patients suffering from peritoneal metastases from colorectal, ovarian, gastric or appendiceal origin. The effectiveness of this extensive has not been elucidated within other rare diseases by now. METHODS: We conducted a retrospective analysis of patients treated with CRS for peritoneal carcinomatosis during the period between July 2010 and September 2015...
October 2017: Annals of Medicine and Surgery
keyword
keyword
78252
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"